SelectScience
Join Free
Accelerating Science
NewsLife Sciences

PlaqueTec recruits first ten patients in BIOPATTERN trial

Life Sciences Society (LSS)

Unique PlaqueTec liquid biopsy system will be used to collect blood samples containing biomolecules localising at or being released by coronary plaque

30 Nov 2023
Natalie Green
Administrator / Office Personnel

Industry news

The BIOPATTERN team Royal Papworth Hospital
The BIOPATTERN team at the Royal Papworth Hospital

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial1 following recruitment of the first ten patients with CAD. The trial has been designed to improve understanding of the pathobiology of atherosclerotic cardiovascular diseases (ACVD) and how it varies between individuals, to aid the development of novel therapies and treatment approaches.

The BIOPATTERN trial will use PlaqueTec’s proprietary blood sampling device, the Liquid Biopsy System™ (LBS), to collect samples at multiple sites along a patient’s diseased coronary artery. Thousands of proteins and other blood molecules will be measured in each sample, enabling the assessment of trans-plaque gradients between samples. These data will be analysed and used to generate a more detailed picture of the disease and enhance clinicians' understanding of which proteins and biomolecules play key roles in CAD progression towards heart attack.

The trial aims to recruit 300 patients with established CAD who have been scheduled for coronary angiography. Patients will be recruited across eight UK NHS specialist cardiac centres, with four sites now open, including the lead site: the Royal Papworth Hospital in Cambridge, UK, where Chief Investigator, Dr. Stephen Hoole is an interventional cardiologist, and Norfolk and Norwich University Hospital, Royal Bournemouth Hospital, and the Bristol Heart Institute. The trial is managed by Papworth Trials Unit Collaboration in collaboration with PlaqueTec, and is overseen by a Trial Steering Committee chaired by Professor Peter Libby (Mallinckrodt Professor of Medicine, Harvard Medical School and President of the International Atherosclerosis Society).

The BIOPATTERN trial will establish the safety and functionality of the LBS device and confirm trans-plaque protein signals seen in earlier pilot studies. PlaqueTec then aims to use the data collected to generate a new data platform based on novel site-of-disease insights to enable the stratification of patients with distinct disease endotypes and the development of precision medicine approaches to improve treatment outcomes for patients with CAD.

“A population approach to managing cardiovascular risk is generally used at present to treat CAD patients and prevent progression to heart attack, whereas a more tailored, precision medicine approach that accounts for each patient’s individual disease profile and health needs has exciting potential benefits. By better targeting of new therapies to those patients at highest risk and who most need them, we hope to efficiently stabilise their disease and improve outcomes,” said Dr Stephen Hoole, Consultant Cardiologist, Royal Papworth Hospital. “The BIOPATTERN trial provides a novel opportunity to use the LBS device to help us better understand and characterise CAD on an individual patient level and potentially enable better patient care by identifying novel precision medicine targeted treatments to improve the outcome of patients with CAD in the future.”

The PlaqueTec LBS has been successfully validated in first-in-human and proof-of-concept trials2.

References:

To find out more about the BIOPATTERN trial, visit www.plaquetec.com

West, N.E.J. et al. (2017) ‘Percutaneous sampling of local biomolecule gradients across coronary artery atherosclerotic plaques’, JACC: Basic to Translational Science, 2(6), pp. 646–654: doi:10.1016/j.jacbts.2017.07.007

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Life Sciences Society (LSS)Company website

Tags

BiosensorsBiosensors are devices used to detect an analyte using biological molecules specific to the analyte coupled to a detector. Biosensor instruments may be photometric, typically using surface plasma resonance (SPR), electrochemical or QCM (quartz crystal microbalance) biosensors. Biosensors should be selective, portable, robust and sensitive and have a fast response time. Systems may be manual or automated and usually have associated software.Protein PurificationProtein purification is a vital step in drug discovery, therapeutics, biotech and life science research. The purification process typically involves subcellular or membrane protein extraction with cell lysis kits, separation of proteins from cell debris by filtration or spin columns, and the isolation of proteins of interest from other proteins and impurities with affinity purification (including fusion protein tags and antibody binding proteins A, G and L), immunoprecipitation or chromatographic methods, such as ion exchange, size exclusion and immobilized metal affinity chromatography. All purification methods come in multiple formats for your laboratory needs, including agarose or magnetic beads, resins, columns and filter plates. Find the best protein purification equipment in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Automated Liquid HandlingAutomated liquid handling equipment is used to mix, dilute and dispense allotted volumes of liquid into microplates and other vessels automatically. The robotic, liquid handling arms can dispense from single channel to 3456 multichannel as well as operate nanoliter dispensing, enabling high throughput of samples. Find the best automated liquid handlers in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Bioprocessing / FermentationBioprocessing is the use of biological materials to perform commercial, scientific or medical research processes. Biological materials used include cells, enzymes and organisms. Usually bioprocessing requires a batch or continuous bioreactor such as a fermentor or cell culture system. The advantages of using a reactor include high productivity, easy configuration, adjustable values and automation.Protein DetectionProtein detection techniques are essential for understanding protein expression, localization, and function. Methods such as western blotting, ELISA, and mass spectrometry are commonly used in research and diagnostics. Browse our peer-reviewed product directory to find the best tools for protein detection, compare products, check reviews, and get pricing directly from manufacturers.BiopharmaceuticalsBiopharmaceuticals are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or for in vivo diagnostics. The most well known example of a biopharmaceutical product, and the first to be approved for therapeutic use, was recombinant human insulin.Liquid HandlingLiquid handling involves the precise transfer, mixing, and dispensing of liquids in laboratory settings. It is essential for accurate and consistent results in biological, chemical, and pharmaceutical research. Automated liquid handling systems improve efficiency and reduce human error in sample preparation and analysis. Explore liquid handling tools in our peer-reviewed product directory; compare products, read customer reviews, and get pricing directly from manufacturers.Liquid BiopsiesLiquid biopsies are non-invasive tests used to detect cancer and other diseases by analyzing blood or other bodily fluids. This technique is gaining popularity for early detection, monitoring treatment response, and detecting minimal residual disease. Explore liquid biopsy solutions in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.

Related articles

PlaqueTec recruits first ten patients in BIOPATTERN trial